HC Wainwright Issues Optimistic Estimate for UTHR Earnings

United Therapeutics Corporation (NASDAQ:UTHR) – Research analysts at HC Wainwright increased their Q3 2026 earnings per share estimates for shares of United Therapeutics in a note issued to investors on Thursday, August 6th. HC Wainwright analyst A. Fein now expects that the biotechnology company will earn $6.60 per share for the quarter, up from their previous estimate of $6.08. The consensus estimate for United Therapeutics’ current full-year earnings is $26.33 per share. HC Wainwright also issued estimates for United Therapeutics’ FY2026 earnings at $26.56 EPS, FY2027 earnings at $30.30 EPS, FY2029 earnings at $46.03 EPS and FY2030 earnings at $55.98 EPS.

A number of other research analysts also recently commented on UTHR. JPMorgan Chase & Co. raised their target price on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Bank of America lowered their price target on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. Morgan Stanley set a $515.00 price objective on shares of United Therapeutics in a report on Thursday, August 6th. Finally, TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $646.00.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $518.27 on Monday. United Therapeutics has a 1-year low of $302.19 and a 1-year high of $609.35. The company has a 50-day moving average of $534.53 and a 200 day moving average of $536.74. The firm has a market cap of $22.23 billion, a PE ratio of 18.54, a price-to-earnings-growth ratio of 1.69 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating the consensus estimate of $6.86 by $0.41. The firm had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same quarter last year, the firm posted $6.41 earnings per share.

Insider Activity at United Therapeutics

In other United Therapeutics news, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $547.61, for a total value of $5,202,295.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares in the company, valued at $22,185,323.93. This trade represents a 19.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $564.11, for a total transaction of $5,641,100.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at $10,648,140.36. This represents a 34.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 452,575 shares of company stock valued at $245,684,184. 8.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Torren Management LLC acquired a new stake in United Therapeutics in the fourth quarter worth about $26,000. Activest Wealth Management increased its holdings in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 56 shares in the last quarter. Fiduciary Financial Advisors acquired a new position in shares of United Therapeutics during the second quarter valued at about $30,000. WealthCollab LLC raised its position in shares of United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares during the last quarter. Finally, Rakuten Securities Inc. boosted its stake in United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 46 shares in the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.